tiprankstipranks
Trending News
More News >
Boiron SA (FR:BOI)
:BOI

Boiron SA (BOI) AI Stock Analysis

Compare
6 Followers

Top Page

FR

Boiron SA

(LSE:BOI)

Rating:62Neutral
Price Target:
€24.50
▲(8.41%Upside)
Boiron SA faces several challenges, particularly with declining revenue and operational efficiency. While the balance sheet remains strong, the technical indicators and high valuation relative to earnings suggest caution. The dividend yield is a positive factor, but overall, the stock presents moderate risk with limited upside in the current environment.

Boiron SA (BOI) vs. iShares MSCI France ETF (EWQ)

Boiron SA Business Overview & Revenue Model

Company DescriptionBoiron SA (BOI) is a French pharmaceutical company that specializes in the production and distribution of homeopathic products. Established in 1932, the company operates in the healthcare sector, offering a wide range of homeopathic medicines and supplements designed to support health and wellness. Boiron is recognized for its commitment to quality and innovation in the field of homeopathy, with a global presence that includes subsidiaries and distribution networks in multiple countries.
How the Company Makes MoneyBoiron SA generates revenue primarily through the sale of its homeopathic products, which include over-the-counter remedies and healthcare supplements. The company's revenue model is centered around its extensive product portfolio that caters to various health needs, such as allergy relief, pain management, and cold and flu symptoms. Boiron leverages its global distribution network to reach pharmacies, healthcare practitioners, and consumers. The company also invests in marketing and education to increase awareness and acceptance of homeopathy as an alternative or complementary healthcare option. Partnerships with healthcare professionals and ongoing research and development efforts contribute to maintaining and expanding its market presence, thereby driving sales and revenue growth.

Boiron SA Financial Statement Overview

Summary
Boiron SA presents a stable balance sheet with low leverage, but faces challenges in revenue growth and profitability. Cash flow generation is strong, but declining trends need attention. Focus should be on reversing revenue decline and improving operational efficiencies.
Income Statement
65
Positive
Boiron SA's income statement shows a decline in total revenue from 2022 to 2024, dropping from €534.2M to €487.6M. The gross profit margin has remained relatively stable, while the net profit margin shows a significant decrease due to declining net income. The company has maintained positive EBIT and EBITDA margins, though both have decreased over the past few years, indicating a reduction in operational efficiency. Overall, the company is facing challenges in maintaining its top-line growth and profitability.
Balance Sheet
72
Positive
The balance sheet of Boiron SA indicates a strong equity position with a debt-to-equity ratio that is very low, showcasing financial stability and low leverage risk. The equity ratio is robust, reflecting good asset management and financial health. However, the declining trend in stockholders' equity and total assets since 2022 suggests potential challenges in asset growth and equity retention.
Cash Flow
68
Positive
Boiron SA's cash flow statement reveals a slight decline in free cash flow over recent years, with a noticeable decrease in both operating cash flow and capital expenditures. The free cash flow to net income ratio remains healthy, indicating strong cash generation relative to profit. However, declining trends in free cash flow growth rate highlight potential concerns in sustaining cash flow levels in the future.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue487.56M493.25M534.24M455.20M513.58M
Gross Profit358.76M358.08M379.73M327.62M394.74M
EBITDA45.46M73.67M91.33M78.75M68.91M
Net Income11.34M35.83M44.67M28.56M26.21M
Balance Sheet
Total Assets576.33M590.20M789.49M770.70M781.82M
Cash, Cash Equivalents and Short-Term Investments64.71M74.04M250.94M234.50M234.69M
Total Debt14.97M13.70M22.17M12.61M12.43M
Total Liabilities198.15M198.70M232.15M238.93M272.65M
Stockholders Equity378.14M393.66M557.62M531.74M509.14M
Cash Flow
Free Cash Flow33.77M27.47M41.51M13.46M47.98M
Operating Cash Flow42.17M45.49M60.10M33.88M68.68M
Investing Cash Flow-18.36M-22.93M-15.28M-11.92M-19.34M
Financing Cash Flow-30.49M-198.41M-28.99M-22.56M-21.93M

Boiron SA Technical Analysis

Technical Analysis Sentiment
Negative
Last Price22.60
Price Trends
50DMA
23.02
Negative
100DMA
23.14
Negative
200DMA
25.32
Negative
Market Momentum
MACD
-0.18
Positive
RSI
47.93
Neutral
STOCH
42.99
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:BOI, the sentiment is Negative. The current price of 22.6 is below the 20-day moving average (MA) of 22.71, below the 50-day MA of 23.02, and below the 200-day MA of 25.32, indicating a bearish trend. The MACD of -0.18 indicates Positive momentum. The RSI at 47.93 is Neutral, neither overbought nor oversold. The STOCH value of 42.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:BOI.

Boiron SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (55)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
76
Outperform
€903.52M15.3610.64%1.16%1.88%5.79%
FRBOI
62
Neutral
€395.92M34.612.94%4.63%-1.15%-68.36%
55
Neutral
€4.86B18.25-49.50%1.91%13.92%-4.82%
52
Neutral
€431.55M-148.98%18.52%
FRAB
49
Neutral
€97.21M
10.52%30.56%
FRIVA
42
Neutral
€364.81M
-47.37%-26.56%
37
Underperform
€556.88M
-1.66%-6.31%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:BOI
Boiron SA
22.65
-7.86
-25.76%
FR:VETO
VETOQUINOL
74.80
-18.39
-19.73%
FR:ABVX
Abivax SA
6.80
-5.54
-44.89%
FR:IVA
Inventiva
2.65
0.19
7.96%
FR:AB
AB Science SA
1.63
0.47
41.15%
FR:MEDCL
MedinCell SA
16.84
1.98
13.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 17, 2025